NASDAQ:AVIR

Atea Pharmaceuticals (AVIR) Stock Price, News & Analysis

Atea Pharmaceuticals logo
$3.99 +0.03 (+0.76%)
Closing price 04:00 PM Eastern
Extended Trading
$3.99 0.00 (0.00%)
As of 04:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Atea Pharmaceuticals Stock (NASDAQ:AVIR)

Advanced

Key Stats

Today's Range
$3.87
▼
$4.03
50-Day Range
$3.96
▼
$5.64
52-Week Range
$2.92
▼
$6.45
Volume
342,250 shs
Average Volume
381,333 shs
Market Capitalization
$320.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00
Consensus Rating
Hold

Company Overview

Atea Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing oral antiviral medicines for serious viral diseases. Its research centers on compounds intended to interfere with viral replication.

The company’s investigational portfolio has included bemnifosbuvir, an oral antiviral candidate studied for COVID-19, as well as programs targeting other viral infections, including dengue. These medicines are investigational and are not established marketed treatments.

Based in Boston, Massachusetts, Atea conducts research and clinical development and has evaluated its candidates in studies involving participants across multiple regions. The company is led by founder and Chief Executive Officer Jean-Pierre Sommadossi.

AI Generated. May Contain Errors.

Atea Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
59th Percentile Overall Score

AVIR MarketRank™: 
2.926193341355 of 5 stars

Atea Pharmaceuticals scored higher than 59% of companies evaluated by MarketBeat, and ranked 913th out of 1,706 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Atea Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 strong buy rating, no buy ratings, 1 hold rating, and 1 sell rating.

  • Upside Potential

    Atea Pharmaceuticals has a consensus price target of $8.00, representing about 100.5% upside from its current price of $3.99.

  • Amount of Analyst Coverage

    Atea Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

  • Read more about Atea Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Atea Pharmaceuticals are expected to grow in the coming year, from ($1.60) to ($1.36) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Atea Pharmaceuticals is -2.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Atea Pharmaceuticals is -2.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Atea Pharmaceuticals has a P/B Ratio of 1.82. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    4.78% of the float of Atea Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Atea Pharmaceuticals has a short interest ratio ("days to cover") of 9.55.
  • Change versus previous month

    Short interest in Atea Pharmaceuticals has recently decreased by 2.02%, indicating that investor sentiment is improving.
  • Dividend Yield

    Atea Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Atea Pharmaceuticals does not have a long track record of dividend growth.

  • News Sentiment

    Atea Pharmaceuticals has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.42 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Atea Pharmaceuticals this week, compared to 2 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Atea Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    21.60% of the stock of Atea Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    86.67% of the stock of Atea Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Atea Pharmaceuticals' insider trading history.
Receive AVIR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Atea Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

AVIR Stock News Headlines

You missed yesterday's deadline…
In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars.tc pixel
Atea Pharma (AVIR) Q3 2026 Earnings Call Transcript
See More Headlines

AVIR Stock Analysis - Frequently Asked Questions

Atea Pharmaceuticals' stock was trading at $3.57 at the beginning of 2026. Since then, AVIR shares have increased by 11.8% and is now trading at $3.99.

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) announced its earnings results on Monday, November, 9th. The company reported ($0.40) EPS for the quarter, beating analysts' consensus estimates of ($0.51) by $0.11.
Read the conference call transcript
.

Atea Pharmaceuticals (AVIR) raised $288 million in an initial public offering (IPO) on Friday, October 30th 2020. The company issued 12,500,000 shares at $22.00-$24.00 per share. J.P. Morgan, Morgan Stanley, Evercore ISI and William Blair acted as the underwriters for the IPO.

Atea Pharmaceuticals' top institutional investors include BML Capital Management LLC (8.42%), State Street Corp (2.03%), Goldman Sachs Group Inc. (0.59%) and Auour Investments LLC (0.21%). Insiders that own company stock include Jean-Pierre Sommadossi, Andrea Corcoran, Franklin M Berger, Bruce Polsky and Wayne Foster.
View institutional ownership trends
.

Shares of AVIR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Atea Pharmaceuticals investors own include Tesla (TSLA), Upstart (UPST), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), PayPal (PYPL), Pfizer (PFE) and Salesforce (CRM).

Company Calendar

Last Earnings
11/09/2026
Today
11/18/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:AVIR
CIK
1593899
Fax
N/A
Employees
55
Year Founded
2014

Price Target and Rating

High Price Target
$8.00
Low Price Target
$8.00
Potential Upside/Downside
+100.5%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.95)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$158.35 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-69.91%
Return on Assets
-61.22%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
8.00
Quick Ratio
8.00

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.19 per share
Price / Book
1.82

Miscellaneous

Outstanding Shares
80,300,000
Free Float
62,958,000
Market Cap
$320.40 million
Optionable
Optionable
Beta
0.76

Social Links

The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

This page (NASDAQ:AVIR) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners